301 related articles for article (PubMed ID: 12018784)
1. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.
Segreti AC; Leung HM; Koch GG; Davis RL; Mohberg NR; Peace KE
J Biopharm Stat; 2001 Nov; 11(4):347-72. PubMed ID: 12018784
[TBL] [Abstract][Full Text] [Related]
2. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence: the regulatory career of a pharmaceutical concept.
Carpenter D; Tobbell DA
Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
[TBL] [Abstract][Full Text] [Related]
4. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
5. Drug development history, "overview," and what are GCPs?
Heilman RD
Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
[TBL] [Abstract][Full Text] [Related]
6. Failing the public health--rofecoxib, Merck, and the FDA.
Topol EJ
N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
[No Abstract] [Full Text] [Related]
7. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
8. Guest editors' note: Special issue associated with the 2013 ASA Biopharmaceutical FDA/Industry Statistics Workshop.
Binkowitz B; Yue LQ
J Biopharm Stat; 2014; 24(5):965-7. PubMed ID: 25014118
[No Abstract] [Full Text] [Related]
9. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
[No Abstract] [Full Text] [Related]
10. Direct-to-consumer prescription drug advertising: history, regulation, and issues.
Huh J; DeLorme DE; Reid LN; An S
Minn Med; 2010 Mar; 93(3):50-2. PubMed ID: 20429178
[TBL] [Abstract][Full Text] [Related]
11. Food and Drug Administration: 100 years of protection.
Mosocco DJ
Home Healthc Nurse; 2007 Mar; 25(3):148-50. PubMed ID: 17353704
[No Abstract] [Full Text] [Related]
12. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
13. Changing requirements for evaluation of pharmacologic agents.
Chesney RW; Christensen ML
Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics and the social history of the controlled clinical trial, 1950-1970.
Podolsky SH
J Hist Med Allied Sci; 2010 Jul; 65(3):327-67. PubMed ID: 20215414
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial drug development--the past, the present, and the future.
Powers JH
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():23-31. PubMed ID: 15522037
[TBL] [Abstract][Full Text] [Related]
16. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
17. Pharmacometrics at FDA: evolution and impact on decisions.
Powell JR; Gobburu JV
Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
[TBL] [Abstract][Full Text] [Related]
18. Déjà Vu at the FDA.
Sharfstein J
Milbank Q; 2017 Jun; 95(2):245-248. PubMed ID: 28378412
[No Abstract] [Full Text] [Related]
19. A brief history of generic substitution in the USA.
Sullivan CG
Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
[No Abstract] [Full Text] [Related]
20. [Magic bullets, chemical gagging, controlled risks? On the research of the network "Pharmaceuticals in the 20th century" of the German Research Foundation (DFG)].
Balz V; Bürgi M; Eschenbruch N; Hulverscheidt M
Medizinhist J; 2008; 43(2):183-201. PubMed ID: 18839933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
